MTF2 and acute myeloid leukemia: As shown in Figure 3A, adrenocortical carcinoma, chromophobe renal cell carcinoma, AML, ovarian serous cystadenocarcinoma, adrenal gland cancers pheochromacytoma and paragngioma, prostate adenocarcinoma, and thyroid carcinoma show at least a 25% reduction in MTF2 transcript levels compared to their normal counterpart tissue.